Advertisement

Topics

Theravance downplays mixed data in GI study

05:50 EDT 2 Aug 2017 | BioPharmaDive

In a Phase 2 study, Theravance's velusetrag turned up statistically significant results for one dose, but failed in others. 

Original Article: Theravance downplays mixed data in GI study

NEXT ARTICLE

More From BioPortfolio on "Theravance downplays mixed data in GI study"

Quick Search
Advertisement